Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback